Literatur
- 1
Lopez A D, Murray C C.
The global burden of disease, 1990 - 2020.
Nat Med.
1998;
11
1241-1243
- 2 European Respiratory Society .European Lung Whithe Book. Lausanne, Switzerland:
European Respiratory Society 2003: 1-182
- 3
ATS/ERS Task Force .
Standards for the diagnosis and treatment of patients with COPD: a summary of the
ATS/ERS position paper.
Eur Respir J.
2004;
23
932-946
- 4
Worth H.
Leitlinie der Deutschen Atemwegsliga und der Deutschen Gesellschaft für Pneumologie
zur Diagnostik und Therapie von Patienten mit chronisch obstruktiver Bronchitis und
Lungenemphysem.
Pneumologie.
2002;
56
703-737
- 5
Hogg J, Coxon H O, Pare P D.
The nature of small-airway obstruction in chronic obstructive pulmonary disease.
N Engl J Med.
2004;
26
2645-2653
- 6
Barnes P J.
Small airways in COPD.
N Engl J Med.
2004;
26
2635-2637
- 7
Gan W Q, Man S PF, Senthilselvan Aet al
.
Association between chronic obstructive pulmonary disease and systemic inflammation:
a systemic review and a metaanalysis.
Thorax.
2004;
59
574-580
- 8
Schols A W, Soeters P J, Dingemans A MCet al
.
Prevalence and characteristics of nutritional depletion in patients with stable COPD
eligible for pulmonary rehabilitation.
Am Rev Respir Dis.
1993;
147
1151-1156
- 9
Schols A W, Slangen J, Volovics Let al
.
Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary
disease.
Am J Respir Crit CareMed.
1998;
157
1791-1797
- 10
Debigare R, Marquis K, Coté C Het al
.
Cataboloc/anabolic balance and muscle wasting in patients with COPD.
Chest.
2003;
124
83-89
- 11
Schols A M.
Nutrition in chronic obstructive pulmonary disease.
Curr Opin Pulm Med.
2000;
6
110-115
- 12
Eid A A, Ionescu A A, Nixon L S. et al .
Inflammatory response and body composition in chronic obstructive pulmonary disease.
Am J Respir Crit Care Med.
2001;
164
1414-1418
- 13
Cohen R I, Marzouk K, Berkosko P. et al .
Body composition and resting energy expenditure in clinically stable, non-weight-losing
patients with severe emphysema.
Chest.
2003;
124
1365-1372
- 14
John M, Hörnig S, Witt C. et al .
Anemia and inflammation in chronic obstructive pulmonary disease.
Chest.
2005;
127
825-829
- 15
John M, Lange A, Hörnig S. et al .
Prevalence of anemia in Chronic Obstructive Pulmonary Disease:Comparison to other
chronic diseases.
Int J Cardiol.
2005;
im Druck
- 16 Agusti A GN. COPD, a muliticomponent disease: implications for management. Respir
Med. Doi: 10.1016/j.rmed.2004.11.006
- 17
Celli B R, Cote C G, Marin J M. et al .
The body mass index, airflow obstruction, dyspnoea, and exercise capacity index in
chronic obstructive pulmonary disease.
N Engl J Med.
2004;
350
1005-1012
- 18 www.goldcopd.com.
- 19
Calverley P, Pauwels R, Vestbo J.
Combined salmeterol and fluticasone in treatment of chronic obstructive pulmonary
disease: a randomised controlled trial.
Lancet.
2003;
361
449-456
- 20
Szafranski W, Cukier A, Ramirez A.
Efficacy and safety of budesonide/formoterol in the management of chronic obstructive
pulmonary disease.
Eur Respir J.
2003;
21
74-81
- 21
Calverley P M, Boonsawat W, Cseke Z.
Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary
disease.
Eur Respir J.
2003;
22
912-919
- 22
O'Donnell D E, Flüge T, Gerken F.
Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD.
Eur Respir J.
2004;
23
832-840
- 23
O'Donnell D E, Voduc N, Fitzpatrick M.
Effect of salmeterol on the ventilatory response to exercise in chronic obstructive
pulmonary disease.
Eur Respir J.
2004;
24
86-94
- 24
Aliverti A, Rodger K, Dellaca R L.
The effect of salbutamol on lung function and chest wall volumes at rest and during
exercise in COPD.
Thorax.
2005;
60
916-924 Epub ahead of print
- 25
National Emphysema Treatment Trial Research Group .
A randomised trial comparing lung-volume-reduction surgery with medical therapy for
severe emphysema.
N Engl J Med.
2003;
348
2059-2073
- 26
Burge S, Wedzicha J A.
COPD exacerbations: definitions and classifications.
Eur Respir J.
2003;
41
46s-53s
- 27
Brunton S, Carmichael B P, Colgan R.
Acute exacerbation of chronic bronchitis: a primary care consensus guideline.
Am J Manag Care.
2004;
10
689-696
- 28
Anthonisen N R, Connett J E, Murray R P. for the Lung Health Study Research Group
.
Smoking and lung function of Lung Health Study participants after 11 years.
Am J Respir Crit Care Med.
2002;
166
675-679
- 29
Long term domicilary oxygen therapy in chronic hypoxic cor pulmonale complicating
chronic bronchitis and emphysema. Report of the Medical Research Council Working Party.
Lancet.
1981;
1
681-686
- 30
Crockett A J, Cranston J M, Moss J R.
Survival on long-term oxygen therapy in chronic airflow limitation: from evidence
to outcomes in the routine clinical setting.
Intern Med J.
2001;
31
448-454
- 31
Sin D, Tu J.
Inhaled corticosteroids and the risk of mortality and readmission in elderly patients
with chronic obstructive pulmonary disease.
Am J Respir Crit Care Med.
2001;
164
580-584
- 32
Soriano J B, Vestbo J, Pride N B.
Survival in COPD patients after use of salmeterol and/or fluticasone propionate in
general practice.
Eur Respir J.
2002;
20
819-825
- 33
Suissa S.
Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease:
immortal time bias in observational studies.
Am J Respir Crit Care Med.
2003;
168
49-53
- 34
The TORCH study group .
The TORCH survival study protocol.
Eur Respir J.
2004;
24
206-210
- 35
Man S FP, Sin D D.
Inhaled corticosteroids in chronic obstructive pulmonary disease. Is there a clinical
benefit?.
Drugs.
2005;
65
579-591
- 36
Sin D D, Lacy P, York E.
Effects of fluticasone on systemic markers of inflammation in chronic obstructive
pulmonary disease.
Am J Respir Crit Care Med.
2004;
170
760-765
- 37
De Melo M N, Ernst P, Suissa S.
Inhaled corticosteroids and the risk of a first exacerbation in COPD patients.
Eur Respir J.
2004;
23
692-697
- 38
Soto J F, Hanania N A.
Selective phosphodiesterase-4 inhibitoprs in chronic obstructive lung disease.
Current Opinion in Pulmonary Medicine.
2005;
11
129-134
- 39
Creutzberg E C, Wouters E F, Mostert R.
A role for anabolic steroids in the rehabilitation of patients with COPD?.
Chest.
2003;
124
1733-1742
- 40
Barnes P J, Hansel T T.
Prospects for new drugs for chronic obstructive pulmonary disease.
Lancet.
2004;
364
985-996
PD. Dr. med. Matthias John
Charité - Universitätsmedizin Berlin · Arbeitsbereich Pneumologie
Schumannstr. 20/21
10098 Berlin
Germany
Email: matthias.john@charite.de
